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ABSTRACT: The expanding “toolbox” of biocatalysts opens 
new opportunities to redesign synthetic strategies to target 
molecules by incorporating a key enzymatic step into the syn-
thesis. Herein, we describe a general biocatalytic approach for 
the enantioselective preparation of 2,6-disubstituted piperi-
dines starting from easily accessible pro-chiral ketoenones. 
The strategy represents a new biocatalytic disconnection, 
which relies on an ω-TA-mediated aza-Michael reaction. Sig-
nificantly, we show that the reversible enzymatic process can 
power the shuttling of amine functionality across a molecular 
framework, providing access to the desired aza-Michael prod-
ucts.   
The intramolecular aza-Michael reaction (IMAMR) is a pow-
erful method for the preparation of simple and architecturally 
complex nitrogen heterocycles and alkaloid skeleta.1  
An ideal strategy for the synthesis of such heterocycles and 
alkaloids is a tandem reductive amination/IMAMR sequence 
(Figure 1), allowing direct, one-pot conversion of readily avail-
able prochiral ketoenones 2 to stereodefined, highly function-
alized cyclic products 1. However, the approach is dependent 
upon amination conditions where there is i) no reduction of 
the double bond, ii) no amination of the enone carbonyl, iii) 
stereoselective amination of the desired ketone and iv) no 
amination of the pendent piperidine ketone. Owing to these 
demands, the strategy outlined in Figure 1 is currently beyond 
traditional chemical synthesis and IMAM strategies are char-
acterised by step-wise introduction of N/O-functionality with 
a consequent reliance on protecting group manipulations.2  
Biocatalysis allows us to reevaluate synthetic strategies and 
enables disconnections that are not possible using traditional 
chemical synthesis or catalysis.3 ω-Transaminase (ω-TA) en-
zymes are emerging as extremely important catalysts for the 
synthesis of optically pure chiral amines starting from readily 
available prochiral ketones.4 Despite the challenges associated 
with the use of ω-TAs, including the necessity for high equiv-
alents of sacrificial amine donor, the application of an (R)-se-
lective ω-TA variant for the industrial-scale synthesis of the 
anti-diabetic drug, Sitagliptin, highlights their enormous syn-
thetic potential.4a These enzymes rely on the cofactor pyri-
doxyl-5’-phosphate (PLP) to mediate the amination of ke-
tones,5 with no requirement for reducing agents, and there-
fore have the potential to be applied effectively for the synthe-
sis of a broad range of piperidines following the strategy out-
lined in Figure 1. While previous studies have shown that ex-
cellent regioselectivity can be achieved in the conversion of 
sterically demanding 1,4- and 1,5-diketones bearing one bulky 
group,6 there is no literature precedence for such selectivity 
on substrates with two accessible ketones. 
 
Figure 1. An attractive retrosynthesis for the preparation of 
heterocycles and alkaloids starting from ketoenones.  
Here we describe a new biocatalytic disconnection for the re-
gio- and stereoselective synthesis of a range of 2,6-disubsti-
tuted piperidines exploiting a key biocatalytic transamination 
followed by a spontaneous IMAMR. Furthermore, for sub-
strates where high regioselectivity is not expected, we specifi-
cally exploit the reversible nature of the biocatalytic amina-
tion process to ensure that the amine functionality is ulti-
mately installed at the desired position in a strategy that 
would not be possible using a classical reductive amination.   
Two commercially available ω-TA biocatalysts from Codexis, 
which have complementary selectivity, were chosen to evalu-
ate the methodology on a small panel of diketones 3a-e. These 
diketones are readily available via oxidative cleavage of 1-
methylcyclopentene followed by reaction with a suitable 
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phosphorus ylid (see ESI). Complete regioselectivity in the 
amination step of ketones 3a-d was anticipated from previous 
literature.6 As expected, both the (S)- and (R)-selective ω-TA 
enzymes mediated the transamination reaction exclusively on 
the methyl ketone in >99% ee (Table 1). Following transami-
nation, a spontaneous IMAMR occurs, providing the 2,6-di-
substituted piperidines7 as a mixture of diastereoisomers. 
Conveniently, epimerization readily occurred upon standing 
in MeOH, presumably via a retro-aza-Michael reaction,8 
providing products 4a-d in >99% de. A particularly important 
aspect of this transformation is the requirement for only 2 
equivalents of the low-cost isopropylamine donor in the ab-
sence of in-situ by-product removal strategies, owing to the 
powerful driving force of the 1,4-addition reaction. Firstly, this 
gave us confidence that the reversible amination strategy 
could be successfully exploited for the conversion of sub-
strates with two accessible ketones. Additionally, employing 
these conditions does not lead to any undesired amination of 
the product pendent ketone. The aza-Michael reaction also 
drives amination of bulkier ketones and a reversal in the se-
lectivity previously observed during transamination of 1,4/1,5-
dicarbonyls.6 Thus, ethylketoenone 3e provides piperidine 4e, 
albeit with reduced yield/ee, using the alternate (S)-selective 
ATA256.8  
Table 1. ω-TA-mediated transamination/IMAMR cas-
cade of ketoenones 3a-e.a  
 
Substrate ω Conv 
(%)b 
ee 
(%)c 
de 
(%)d 
Yield  
(%)e 
3a ATA113 >99f >99 >99g  78 (S,S)h 
3a ATA117 >99f >99 >99g 88 (R,R)h 
3b ATA113 >99 >99 >99 92 (S,S)h 
3bi ATA117 >99f >99 >99 90 (R,R)h 
3c ATA113 >99 >99 >99 76 (S,S)h 
3ci ATA117 50f >99 >99 44 (R,R)h 
3d ATA113 >99 >99 >99j 72 (S.S)h 
3d ATA117 >99 >99 >99j 70 (R,R)h 
3ei,k ATA256 >99f 70l >99 50(S,S)h, 
a Reaction conditions: (i) ω-TA (5 mg/mL), substrate (50 mM), iso-
propylamine (100 mM), pyridoxyl-5’-phosphate (PLP, 2 mM), HEPES 
buffer (100 mM, pH 7.5), 30 °C, 150 RPM, 24 h; (ii) MeOH, r.t., 24 h. b 
Conversion determined by 1H-NMR after 24 h. c ee determined by chi-
ral GC or HPLC (see ESI). d de determined by NMR after the epimeri-
zation step. e Isolated yield after flash chromatography. f Conversion 
after 48 h. g Epimerization was carried out at 65 oC for 24 h. h Config-
uration assigned by analogy with 3f and in agreement with NOESY 
experiments (see ESI). i 4 equivalents of isopropylamine were used. j 
Epimerization was carried out in EtOH at 80 oC for 24 h. k Reaction 
carried out at 50 oC. l See reference 8. 
In light of this, it was envisaged that the same methodology 
could be employed to access the naturally occurring defense 
alkaloid ()-pinidinone 4f9,10 from the corresponding dimethyl 
ketoenone 3f (Scheme 1). An additional level of complexity is 
associated with this diketone as the ω-TA is not expected to 
show any regioselectivity in the amination step. We reasoned 
that while two amine products would initially be formed re-
sulting from amination of the methyl ketone and enone, the 
reversible nature of the biocatalytic amination coupled with 
the spontaneous 1,4-addition would drive the shuttling of the 
undesired amine to allow exclusive isolation of ()-pinidinone 
4f and trans-5f. As expected, incubation of 3f with ATA117 af-
forded a mixture of diastereoisomers 4f and 5f with >99% con-
version and >99% ee, which was easily epimerized to ()-
pinidinone 4f with >99% de (Table 2). Comparable results 
were obtained with (S)-selective ATA113. We have also demon-
strated that 1.1 equivalents of the amine donor were sufficient 
to achieve >99% conversion (Table 2, footnote f). The syn-
thetic utility of our methodology is showcased by the ease of 
upscaling, allowing access to 0.48 g of ()-pinidinone employ-
ing only 2 eq of isopropylamine (Scheme 1).  
Table 2. Results from biotransformations with 3f em-
ploying ATA113 and ATA117.a  
Substrate ω
 
Conv 
(%)b 
ee 
(%)c 
de 
(%)d 
Yield  
(%)e 
3f ATA113 >99f >99 >99 91 (S,S)g 
3f ATA117 >99f >99 >99 90 (R,R)g 
a-e See Table 1 footnotes. f This transformation could also be carried out 
using 1.1 eq. of isopropylamine (55 mM) with identical conversion. g 
Absolute configuration determined by correlation with known com-
pounds (see ESI).   
Scheme 1. Preparative scale conversion of 3f to 4f ()-
pinidinone using (R)-selective ATA117.  
 
To support our hypothesis that the amine functionality can be 
shuttled across the molecular framework, amino ketone 6f 
was synthesized in 5 steps (see ESI) and exposed to ATA117 in 
the absence of any additional amine donor or acceptor 
(Scheme 2). After 24 h, complete consumption of 6f was ob-
served along with the formation of a mixture of ()-pinidinone 
4f and trans-5f. To our knowledge, this is the first example of 
an ω-TA reaction that does not require a separate donor and 
acceptor. The enzyme bound PLP forms pyridoxamine phos-
phate (PMP) using 6f as the amine donor and generates 
diketone 3f. The amine functionality is then shuttled to the 
more thermodynamically stable ketone, which readily under-
goes an IMAMR. While bis-amine 7f was not observed during 
the course of the reaction, it is likely that it is an intermediate. 
The efficiency of this conversion is striking, as the single 
amine equivalent available in the reaction has come from the 
starting material 6f.   
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Scheme 2. Proposed mechanism for the formation of ()-
pinidinone 4f and trans-5f from the single amine equiva-
lent 6f. 
 
In conclusion, we have developed an extremely efficient bio-
catalytic aza-Michael strategy for the enantioselective conver-
sion of pro-chiral ketoenones to 2,6-disubstituted piperidines, 
with excellent conversion and isolated yield. Our approach re-
veals that coupling a reversible ω-TA reaction with a strong 
thermodynamic driving force allows the amine functionality 
to be shuttled across a molecular framework to form the de-
sired product. This work significantly expands the scope of ω-
TA methodology in total synthesis and we are currently ex-
ploring the utility of this dynamic chemistry for the synthesis 
of more complex alkaloid scaffolds.  
The supporting information contains details of compound prepara-
tion, characterization and NMR/GC/HPLC spectra. This material is 
available free of charge via the Internet at http://pubs.acs.org.  
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